Cancer Biologics Market Trends in 2025

Published: November 2025

Cancer is recognized as one of the deadliest diseases across the world. Currently, several conventional treatments, including surgery, radiation therapy and chemotherapy are available for the treatment of various types of cancer. However, these approaches often fail to address the genetic heterogeneity of tumors, which vary across individuals. Over the past decade, cancer biologics, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, and cell and gene therapies, have transformed cancer treatment by offering higher selectivity, improved safety profiles, and potential for long-term disease control. Additionally, the patent expiration for several blockbuster monoclonal antibodies have encouraged drug developers to redesign these drugs and / or find new analogues.

To further improve the efficacy and safety of monoclonal antibodies, the drug developers have gradually shifted their focus towards the development of next generation recombinant antibodies, such as bispecific antibodies. Bispecific antibodies are novel class of antibody therapeutics that act by simultaneously binding two distinct antigens (or different epitopes of the same antigen). By leveraging various mechanisms, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), bispecific antibodies efficiently redirect immune effector cells to identify and eliminate tumor cells. Alongside rapid advancements in cell and gene therapies, and mRNA therapies and vaccines, these modalities are likely to be one of the highest valued markets within biopharmaceutical industry for cancer treatment.

Roots Analysis has conducted an exhaustive study on Cancer Biologics Market featuring the current landscape and future opportunity for the companies engaged in the cancer biologics domain. In this article, we have highlighted some of the cancer biologic market trends 2025 that are likely to shape the evolution of this sector during the forecast period.

Discover The Key Market Trends in Cancer Biologics Market

Want to explore more about Cancer Biologics Market?

Cancer Biologics Market Trends 2025 That Are Likely to Shape the Future Potential of the Industry

1. Monoclonal Antibodies: Dominating the Antibody Market for Cancer

Monoclonal antibodies (mAbs) are highly specialized, engineered proteins, designed to precisely target specific cells within the body. These antibodies are derived from a single, cloned immune cell and ensure that they bind to a single or unique epitope (a specific part of an antigen). Notably, close to 45% of the monoclonal antibodies market is likely to be captured by cancer biologics. This can be attributed to various advantages offered by them, including high target specificity, minimal side effects and better immune response.

In June 2025, Medicines and Healthcare products Regulatory Agency approved HETRONIFLY®, the first PD-L1 monoclonal antibody for the treatment of adults suffering from extensive stage small cell lung cancer.

2. Cell and Gene Therapies: Upsurge in Approval of Therapies for Cancer Treatment

In the past few years, there has been an increase in number of approvals of cell and gene therapies for cancer treatment. This can be attributed to shift towards personalized medicine coupled with expeditated regulatory approvals. Notably, cell and gene therapies offer various advantages, including high specificity to recognize and specifically attack tumor cells and prolonged disease remission rates, omitting the need for further treatments. Notably, in November 2025, ImmunoACT announced its CAR-T cell therapy, NexCAR19 for the treatment of various type of cancers, including multiple myeloma, relapsed or refractory B-cell leukemia and glioblastoma.

3. mRNA Therapies and vaccines: Emergence of Blockbuster Drugs

The mRNA vaccines and therapeutics (including BNT113, mRNA 4157 and GRT-C901 / GRT-R902), have shown promising results in the clinical trials and are poised to achieve blockbuster status in the coming years. These innovative mRNA-based treatment works by encoding tumor-specific antigens or neoantigens, thereby stimulating a patient’s immune system to recognize and attack cancer cells more effectively. Further, these mRNA therapies can be personalized for individual patients, enhancing their effectiveness by targeting unique tumor mutations.

4. Partnerships and Collaborations: Fostering Progress and Innovation

Over the past few years, the cancer biologics domain has witnessed various types of partnerships in order to expand their respective portfolio and gain additional capabilities related to cancer biologics. In October 2025, Takeda entered into strategic collaboration with Innovent Biologics, aimed to co-develop and commercialize innovative biologic therapies (focusing on next-generation immune-oncology drugs) for cancer.

5. Key Market Movers: Look How Big Players are Influencing the Market

In past few years, numerous big pharmaceutical companies have played an important role in advancing cancer biologics market by actively engaging in strategic partnerships with other drug developers, making substantial investments, expanding their operational capabilities, and acquiring innovative firms. Notably, many large companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, and Merck are significantly investing in cancer biologics. In 2025, Bristol Myers Squibb announced the USD 11 billion deal with BioNTech, aimed to accelerate immuno-oncology innovation.

6. North America: Leading the Cancer Biologics Market

Currently, North America captures majority (~45%) of the market share as per the cancer biologics industry analysis. Notably, cancer accounts for nearly 20 million new cases and 10 million deaths in the US alone.[1] This can be attributed to the increasing investment in oncology by drug developers established in this region and growing demand for advanced cancer treatment. Further, ongoing technological advancements along with robust research capabilities within this region is propelling the cancer biologics market in North America during the forecast period.

Conclusion

The cancer biologics industry analysis highlights the likely potential of advanced biologic therapies to transform the global oncology landscape, offering more targeted and personalized cancer treatment options. These biologics, including monoclonal antibodies, bispecific and multi-specific antibodies, cell and gene therapies, oncolytic viral therapies, and peptides are redefining therapeutic paradigm across various type of cancer. Further, as scientific understanding of cancer biologics deepens and regulatory pathways for biologics evolve, the cancer biologics industry is likely to witness a notable wave of innovation, collaboration, and technological expansion.

Browse our full report on Cancer Biologics Market: https://www.rootsanalysis.com/reports/cancer-biologics-market.html

Sources